Aethlon Medical (NASDAQ:AEMD) Releases Quarterly Earnings Results, Misses Expectations By $0.44 EPS

Aethlon Medical (NASDAQ:AEMD) announced its quarterly earnings results on Thursday. The medical equipment provider reported ($2.45) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($2.01) by ($0.44), Zacks reports.

Here are the key takeaways from Aethlon Medical’s conference call:

• Aethlon reported continued progress in its Australian oncology trial: cohort 1 (single Hemopurifier treatment) showed no device‑related SAEs or DLTs and directional EV and immune cell improvements, cohort 2 has two treatments completed with a third patient due by end of February, and an independent DSMB is expected to meet in late March to decide whether to advance to cohort 3.
• Patient recruitment has accelerated after contracting TrialFax and Dedicated for online advertising and phone pre‑screening, creating a referral queue that could enable rapid enrollment into cohort 3 if the DSMB approves advancement.
• A material‑transfer study with Stavro is testing compatibility of the Hemopurifier with a simplified SLAMB pump and single‑lumen catheter that could enable infusion‑center or oncology‑unit use, but lab compatibility studies, ex‑vivo EV capture testing and future regulatory submissions will be required.
• R&D work expands beyond oncology — preclinical data show the Hemopurifier’s GNA resin binds EVs and lowers immune‑dysregulating microRNAs in Long COVID samples, and the company is exploring viral cargo and platelet‑derived EV removal to support a potential multi‑indication strategy.
• Financially, Aethlon had approximately $7 million in cash at December 31, 2025 and posted a quarterly operating loss of $2.06M (up vs prior year quarter), although nine‑month operating expenses fell 27% YoY — a modest cash position that could limit near‑term execution without additional funding.

Aethlon Medical Stock Down 1.0%

AEMD opened at $1.96 on Friday. Aethlon Medical has a 52 week low of $1.86 and a 52 week high of $53.27. The stock has a market cap of $1.91 million, a PE ratio of -0.09 and a beta of 1.60. The business has a 50 day moving average of $2.71 and a 200-day moving average of $6.26.

Analysts Set New Price Targets

Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of Aethlon Medical in a research note on Wednesday, January 21st. One investment analyst has rated the stock with a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock has an average rating of “Reduce” and a consensus price target of $560.00.

Institutional Trading of Aethlon Medical

An institutional investor recently bought a new position in Aethlon Medical stock. Citadel Advisors LLC purchased a new position in Aethlon Medical, Inc. (NASDAQ:AEMD) in the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission. The firm purchased 95,084 shares of the medical equipment provider’s stock, valued at approximately $71,000. Citadel Advisors LLC owned approximately 36.57% of Aethlon Medical at the end of the most recent reporting period. 1.99% of the stock is currently owned by institutional investors and hedge funds.

Aethlon Medical Company Profile

Aethlon Medical, Inc (NASDAQ: AEMD) is a clinical‐stage biotechnology company focused on developing novel immunotherapeutic medical devices to address life‐threatening diseases. The company’s lead product candidate, the Hemopurifier®, is an extracorporeal affinity device designed to remove circulating viruses and immunosuppressive exosomes from the bloodstream. By targeting glycosylated pathogens and exosomes, Aethlon aims to restore immune function and improve patient outcomes in oncology and infectious disease settings.

The Hemopurifier platform leverages proprietary lectin affinity technology to selectively bind and eliminate harmful particles without depleting healthy blood components.